| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
TS-IN-8 (Compound 4d) (1-80 μM, 24 hours) showed strong inhibitory effects on MCF-7 cells (IC50 = 10.11 μM) and A549 cells (IC50 = 22.49 μM), weaker inhibitory effects on HepG2 cells, and low toxicity to normal McCoy cells (IC50 = 115.86 μM)[1]. TS-IN-8 (1-5 μM, 24 hours) induced apoptosis in MCF-7 cells in a dose-dependent manner and caused cell cycle arrest in the G2/M phase[1]. TS-IN-8 (1-5 μM, 24 hours) induced dose-dependent nuclear morphological changes in MCF-7 cells, including chromatin condensation at 1 μM (apoptotic nuclear index 4.12%) and nuclear fragmentation with apoptotic body formation at 5 μM (apoptotic nuclear index 8.97%). Furthermore, TS-IN-8 significantly increased intracellular reactive oxygen species (ROS) levels and activated endogenous apoptosis pathways by regulating the bax/bcl-2 ratio and caspase activation [1]. TS-IN-8 (1-5 μM, 6 hours) significantly reduced TS protein expression in MCF cells [1]. TS-IN-8 (1-5 μM, 24 hours) inhibited the migration of MCF-7 cells in a dose-dependent manner [1]. TS-IN-8 (1-5 μM, 24 hours) disrupts the structural integrity of 3D tumor spheres, reduces the number of live cells in 3D spheres, and increases the proportion of dead cells [1].
|
|---|---|
| Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: MCF-7 cells, A549 cells, HepG2 cells, McCoy cells Tested Concentrations: 1 μM, 5 μM, 10 μM, 20 μM, 40 μM, 60 μM, 80 μM Incubation Duration: 24 h Experimental Results: Showed strong inhibitory effects on MCF-7 cells (IC50 = 10.11 μM) and A549 cells (IC50 = 22.49 μM), weaker inhibitory effects on HepG2 cells, and low toxicity to normal McCoy cells (IC50 = 115.86 μM). Apoptosis Analysis[1] Cell Types: MCF-7 cells Tested Concentrations: 1 μM, 5 μM Incubation Duration: 24 h Experimental Results: At 1 μM, the proportion of apoptotic cells increased to 3.27 %; at 5 μM, the proportion of apoptotic cells increased to 6.49 %. Cell Cycle Analysis[1] Cell Types: MCF-7 cells Tested Concentrations: 1 μM, 5 μM Incubation Duration: 24 h Experimental Results: At 1 μM, the percentage of cells in the G2/M phase increased to 34.8 %; at 5 μM, the percentage of cells in the G2/M phase increased to 39.8 %. Western Blot Analysis[1] Cell Types: MCF-7 cells Tested Concentrations: 1 μM, 5 μM Incubation Duration: 24 h Experimental Results: Pro-apoptotic protein Bax expression was upregulated, while anti-apoptotic proteins Bcl-2 and Survivin expression were downregulated. The cleavage patterns of Caspase-3, Caspase-9, and PARP-1 were increased. An elevated Bax/Bcl-2 ratio indicates activation of the mitochondrial pathway for apoptosis. Western Blot Analysis[1] Cell Types: MCF-7 cells Tested Concentrations: 1 μM, 5 μM Incubation Duration: 24 h Experimental Results: TS protein expression levels were reduced (0.8-fold compared to the control at 1 μM and 0.6-fold compared to the control at 5 μM). Cell Migration Assay [1] Cell Types: MCF-7 cells Tested Concentrations: 1 μM, 5 μM Incubation Duration: 24 h Experimental Results: At 1 μM, reduced the wound closure rate to 68.4 %; at 5 μM, reduced the wound closure rate to 55.6 %. |
| References |
| Molecular Formula |
C19H20FN3O3S
|
|---|---|
| Molecular Weight |
389.44
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5678 mL | 12.8389 mL | 25.6779 mL | |
| 5 mM | 0.5136 mL | 2.5678 mL | 5.1356 mL | |
| 10 mM | 0.2568 mL | 1.2839 mL | 2.5678 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
